Is a third SARS‐CoV‐2 vaccine dose efficient in allogeneic haematopoietic cell transplant recipients?

When and how often should allogeneic haematopoietic cell transplantation recipients be vaccinated against severe acute respiratory syndrome coronavirus‐2 (SARS‐CoV‐2) is unclear. The report by Bankova et al. suggests that a third SARS‐CoV‐2 vaccine dose is important but still insufficient in some pa...

Descripción completa

Detalles Bibliográficos
Autor principal: Spyridonidis, Alexandros
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Commentary
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9878174/
https://www.ncbi.nlm.nih.gov/pubmed/36477621
http://dx.doi.org/10.1111/bjh.18591
_version_ 1784878445063307264
author Spyridonidis, Alexandros
author_facet Spyridonidis, Alexandros
author_sort Spyridonidis, Alexandros
collection PubMed
description When and how often should allogeneic haematopoietic cell transplantation recipients be vaccinated against severe acute respiratory syndrome coronavirus‐2 (SARS‐CoV‐2) is unclear. The report by Bankova et al. suggests that a third SARS‐CoV‐2 vaccine dose is important but still insufficient in some patients to establish an adequate humoral response. Commentary on: Bankova et al. Antibody response to a third SARS‐CoV‐2 vaccine dose in recipients of an allogeneic hematopoietic cell transplantation. Br J Haematol. 2022 (Online ahead of print). doi: 10.1111/bjh.18562. xxx
format Online
Article
Text
id pubmed-9878174
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-98781742023-01-26 Is a third SARS‐CoV‐2 vaccine dose efficient in allogeneic haematopoietic cell transplant recipients? Spyridonidis, Alexandros Br J Haematol Commentary When and how often should allogeneic haematopoietic cell transplantation recipients be vaccinated against severe acute respiratory syndrome coronavirus‐2 (SARS‐CoV‐2) is unclear. The report by Bankova et al. suggests that a third SARS‐CoV‐2 vaccine dose is important but still insufficient in some patients to establish an adequate humoral response. Commentary on: Bankova et al. Antibody response to a third SARS‐CoV‐2 vaccine dose in recipients of an allogeneic hematopoietic cell transplantation. Br J Haematol. 2022 (Online ahead of print). doi: 10.1111/bjh.18562. xxx John Wiley and Sons Inc. 2022-12-07 /pmc/articles/PMC9878174/ /pubmed/36477621 http://dx.doi.org/10.1111/bjh.18591 Text en © 2022 The Author. British Journal of Haematology published by British Society for Haematology and John Wiley & Sons Ltd. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
spellingShingle Commentary
Spyridonidis, Alexandros
Is a third SARS‐CoV‐2 vaccine dose efficient in allogeneic haematopoietic cell transplant recipients?
title Is a third SARS‐CoV‐2 vaccine dose efficient in allogeneic haematopoietic cell transplant recipients?
title_full Is a third SARS‐CoV‐2 vaccine dose efficient in allogeneic haematopoietic cell transplant recipients?
title_fullStr Is a third SARS‐CoV‐2 vaccine dose efficient in allogeneic haematopoietic cell transplant recipients?
title_full_unstemmed Is a third SARS‐CoV‐2 vaccine dose efficient in allogeneic haematopoietic cell transplant recipients?
title_short Is a third SARS‐CoV‐2 vaccine dose efficient in allogeneic haematopoietic cell transplant recipients?
title_sort is a third sars‐cov‐2 vaccine dose efficient in allogeneic haematopoietic cell transplant recipients?
topic Commentary
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9878174/
https://www.ncbi.nlm.nih.gov/pubmed/36477621
http://dx.doi.org/10.1111/bjh.18591
work_keys_str_mv AT spyridonidisalexandros isathirdsarscov2vaccinedoseefficientinallogeneichaematopoieticcelltransplantrecipients

Ejemplares similares